Pain Detecting and Analgesic Stimulating Device on Low Back Pain

Not Applicable

Completed

• Conditions: Chronic Low Back Pain
• Interventions: Other: Sham; Device: Stimulation

• Registration Number: NCT02256410
• Lead Sponsor: Vrije Universiteit Brussel

Brief Summary

Purpose of study is to test in a randomized controlled trial (RCT) the effects of the Nervomatrix device on various clinical outcomes of patients with low back pain, as well as its mechanisms of action.

Detailed Description

This will be a matched randomized-controlled trial - RCT. Using random numbers from a random number generator, pairs of patients will be randomized to either the Nervomatrix stimulation (experimental group) or to sham stimulation (controls). Matching of pairs will be done based on the baseline data of the primary outcomes - pain and disability, as well as on other treatments received.

Study Timeline

• Study Start: 2013-12
• Study First Submitted: 2013-12-13
• Study First Submitted QC: 2014-10-02
• Study First Posted: 2014-10-03
• Primary Completion: 2014-12
• Study Completion: 2015-02
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-08
• Last Update Posted: 2016-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• chronic low back pain persisting for at least 3 months

Exclusion Criteria

• patho-anatomical diagnosis (such as fractures, tumors, rheumatic diseases and neurological diseases)
• initiated a new conventional therapy during the study period
• pregnant
• patients having a cardiac pacemaker, implanted defibrillator, or other implanted metallic or electronic device

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
sham stimulation	Sham	Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
Stimulation	Stimulation	Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.

Primary Outcome Measures

Name	Time	Method
The change in the amount of steps climbed during one minute	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	Stair climbing: Participants were asked to climb up and down 5 stairs for 1 minute, using the rail for support if required. The total amount of steps climbed will be recorded

Secondary Outcome Measures

Name	Time	Method
The change in central sensitization inventory	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	Part A of 25 statements related to current health symptoms. Each of these items is measured on a 5-point temporal Likert scale, with the following numeric rating scale: never (0), rarely (1), sometimes (2), often (3), and always (4). A cumulative score ranges from 0 to 100. Additionally information is collected in Part B on previously diagnosed central sensitivity syndromes and related conditions.
The change in Pain Catastrophizing Scale	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	will be used to assess pain catastrophizing. It consists of 13 items describing different thoughts and feelings that individuals may experience when they are experiencing pain. Items are scored on a 5-point scale, and total scores are counted by adding up all individual items scores. Higher scores correspond to more severe catastrophic thoughts about pain.
The change in revised Illness perception questionnaire	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	will be used for assessing the patients' illness perceptions, as it is known that patients with maladaptive illness perceptions (e.g. expecting that their back problem will last for a long time, or holding weak beliefs in the controllability of their back problem) are more likely to have poor clinical outcomes 6 months after they consulted their physician
The change in Tampa Scale of Kinesiophobia	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	Tampa Scale of Kinesiophobia is a 17-item questionnaire developed to measure the fear of movement and (re)injury. Each item is scored on a four-point Likert scale ranging from "strongly disagree" \[1\] to "strongly agree" \[4\]. Ratings are added up to give a total score ranging from 17-68 points, with the higher values reflecting greater fear of (re)injury
The change in average pain intensity	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	average pain rating in the last seven days using a 100 mm Visual Analogue Scale (VAS)
The change in Quebec Back Pain Disability Scale	measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)	This questionnaire consists of 20 activity related questions which the patient has to score on a six points scale (0= no; 5= not capable to perform the activity). The total score represents a percentage of functional limitations the patient experiences during daily life.

Trial Locations

Locations (1)

Vrije Universiteit Brussel; 🇧🇪 Brussel, Belgium